Most previous studies regarded Hsp90 chaperone as one machinery and inhibited Hsp90 activities in cancer models and clinical trials with pan-Hsp90i, which may largely account for the disappointing clinical performance of Hsp90 inhibition in cancer treatment so far. This evidence concerns the gene HSP90AB1 and cancer.